Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 19:21:140-143.
doi: 10.1016/j.jdcr.2022.01.005. eCollection 2022 Mar.

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma

Christina D Enescu  1 , Christina Artz  2 , Anna Axelson  2
Affiliations
Case Reports

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma

Christina D Enescu et al. JAAD Case Rep. .
No abstract available

Keywords: EV, enfortumab vedotin; MMAE, monomethyl auristatin E; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; UC, urothelial carcinoma; cutaneous drug toxicity; enfortumab vedotin; exfoliative dermatitis; general dermatology.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Exfoliative dermatitis secondary to enfortumab vedotin. Large, well-demarcated, desquamated patches along the anterior and posterior aspects of the lower parts of the legs.
Fig 2
Fig 2
Patches of erythema on the proximal aspects of the thighs, developing into erythematous plaques with multiple tense bullae on the medial-anterior aspects of the shins bilaterally, with patches of hyperpigmentation and hypopigmentation from prior desquamation on the lower extremities.
Fig 3
Fig 3
Low-power magnification demonstrating focal interface dermatitis with necrotic keratinocytes and full-thickness epidermal necrosis (Hematoxylin-eosin stain; original magnification: ×100).
Fig 4
Fig 4
Clearer interface dermatitis with keratinocyte necrosis (Hematoxylin-eosin stain; original magnification: ×200).
See this image and copyright information in PMC

References

    1. Rosenberg J.E., O'Donnell P.H., Balar A.V., et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–2600. doi: 10.1200/JCO.19.01140. - DOI - PMC - PubMed
    1. Viscuse P.V., Marques-Piubelli M.L., Heberton M.M., et al. Case report: Enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction. Front Oncol. 2021;11:621591. doi: 10.3389/fonc.2021.621591. - DOI - PMC - PubMed
    1. Francis A., Jimenez A., Sundaresan S., Kelly B. A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis. JAAD Case Rep. 2020;7:57–59. doi: 10.1016/j.jdcr.2020.10.020. - DOI - PMC - PubMed
    1. Wu S., Adamson A.S. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. Dermatol Online J. 2019;25(2):13030–qt4j44w7w6. - PubMed
    1. Sasaki R., Fujimura T., Lyu C., Aiba S. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin. J Dermatol. 2020;47(12):1436–1438. doi: 10.1111/1346-8138.15577. - DOI - PubMed

Publication types

LinkOut - more resources